Prescription Drugs:

Implications of Drug Labeling and Off-Label Use

T-HEHS-96-212: Published: Sep 12, 1996. Publicly Released: Sep 12, 1996.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

GAO discussed off-label drug use and its impact on drug promotion and advertising. GAO noted that: (1) off-label drug use is a prevalent phenomenon because the drug industry feels overly constrained by labels in its ability to promote pharmaceutical products; (2) physicians can use approved drugs for conditions or patients other than those listed on the drugs' labels, but manufacturers cannot advertise or promote such use; (3) the extent of off-label drug use has not been documented, but there is evidence that off-label use is common among cancer, acquired immunodeficiency syndrome, and pediatric populations; (4) in the past, off-label use caused reimbursement problems, but 1993 legislation has led insurers to rely on additional sources of information in making their reimbursement decisions; (5) Congress is considering legislation to allow manufacturers to base their advertising and promotion on reputable sources of drug use information in addition to drug labels; (6) the benefits of such an approach include avoiding the cost of supplemental drug approval applications and allowing earlier promotion, but some promising off-label drug uses have been ineffective or harmful to patients; (7) the Food and Drug Administration (FDA) could expedite its approval process by updating labels to list new drug uses; and (8) FDA has improved its timeliness in processing drug applications and efficacy supplements and has changed the evidence requirements for drug use approval under certain circumstances.

Feb 24, 2021

Feb 17, 2021

Feb 11, 2021

Feb 5, 2021

Jan 28, 2021

Jan 21, 2021

Jan 14, 2021

Looking for more? Browse all our products here